Coeliac disease comprises intolerance against dietary wheat, rye and barley gluten and is one of the most common food-related life-long disorders in Western countries. In 2013, new knowledge of the clinical diversity of coeliac disease and further details about the autoimmune aspects of this disorder have emerged.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
The changing clinical profile of celiac disease: a 15-year experience (1998-2012) in an Italian referral center
BMC Gastroenterology Open Access 18 November 2014
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Mäki, M. Coeliac disease and autoimmunity due to unmasking of cryptic epitopes? Lancet 348, 1046–1047 (1996).
Simon-Vescei, Z. et al. A single conformational transglutaminase 2 epitope contributed by three domains is critical for celiac antibody binding and effects. Proc. Natl Acad. Sci. USA 109, 431–436 (2012).
Di Niro, R. et al. High abundance of plasma cells secreting transglutaminase 2-specific IgA autoantibodies with limited somatic hypermutation in celiac disease intestinal lesion. Nat. Med. 18, 441–445 (2012).
Ivarsson, A. et al. Prevalence of childhood celiac disease and changes in infant feeding. Pediatrics 131, e687–e694 (2013).
Sjöberg, V. et al. Intestinal T-cell responses in celiac disease—impact of celiac disease associated bacteria. PLoS ONE 8, e53414 (2013).
Kiefte-de Jong, J. C. et al. Levels of autoantibodies against tissue transglutaminase during pregnancy are associated with reduced fetal weight and birth weight. Gastroenterology 144, 726–735 (2013).
Kalliokoski, S. et al. Celiac disease—specific TG2-targeted autoantibodies inhibit angiogenesis ex vivo and in vivo in mice by interfering with endothelial cell dynamics. PLoS ONE 8, e65887 (2013).
Iversen, R. et al. Transglutaminase 2-specific autoantibodies in celiac disease target clustered, N-terminal epitopes not displayed on the surface of cells. J. Immunol. 190, 5981–5991 (2013).
Lebwohl, B. et al. Mucosal healing and risk for lymphoproliferative malignancy in celiac disease. A population based cohort study. Ann. Intern. Med. 159, 169–175 (2013).
Kaukinen, K. et al. Advances in the treatment of coeliac disease: an immunopathogenetic perspective. Nat. Rev. Gastroenterol. Hepatol. http://dx.doi.org/10.1038/nrgastro.2013.141.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
M. Mäki is a member of the Scientific Advisory Board of Alvine Pharmaceuticals, ImmusanT and Flamentera, member of the Clinical Advisory Board of BioLineRx, chair of the Scientific Advisory Board of Finnish Celiac Society, consultant for Finn Medi and founder and owner of Maki HealthTech. K. Kaukinen declares no competing interests.
Rights and permissions
About this article
Cite this article
Kaukinen, K., Mäki, M. New insights in dietary-gluten-induced autoimmunity. Nat Rev Gastroenterol Hepatol 11, 80–82 (2014). https://doi.org/10.1038/nrgastro.2013.232
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2013.232
This article is cited by
-
Italienische Arbeitsgruppe will Evidenz der NCGS gezeigt haben
Allergo Journal (2016)
-
The changing clinical profile of celiac disease: a 15-year experience (1998-2012) in an Italian referral center
BMC Gastroenterology (2014)